Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30663731 | 0.84 | MAPT (0.56) | MAOBMAPTCYP3A4CYP2A6MAOA | |
| SCHEMBL10347560 | 0.84 | MAPT (0.56) | MAOBMAPTCYP3A4CYP2A6MAOA | |
| SCHEMBL9670160 | 0.84 | MAOB (0.49) | MAOBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL21694039 | 0.82 | MAPT (0.55) | MAOBMAPTCYP3A4CYP2A6MAOA | |
| SCHEMBL20530607 | 0.81 | CYP3A4 (0.49) | MAOBALDH1A1MAPTCYP3A4CYP2A6 | |
| SCHEMBL20530567 | 0.80 | MAOB (0.49) | MAOBALDH1A1MAPTCYP3A4CYP2A6 | |
| SCHEMBL7347123 | 0.79 | ALDH1A1 (0.55) | MAOBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2061468 | 0.79 | ALDH1A1 (0.55) | MAOBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL26013294 | 0.78 | MAOB (0.64) | MAOBCYP1A2MAPTCYP3A4CYP2A6 | |
| SCHEMBL20530601 | 0.77 | IDO1 (0.52) | MAOBALDH1A1MAPTCYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100554251-C | A kind of maleimide derivatives and preparation method thereof | CHINESE ACAD INST CHEMISTRY (CN) | 2009-10-28 | — | — | CN | claimed |
| CN-1896058-A | Maleimide derivative and its preparation | CHINESE ACAD INST CHEMISTRY (CN) | 2007-01-17 | — | — | CN | claimed |
| EP-4716533-A2 | FLUORESCENT INDICATORS FOR METAL ION DETECTION AS SUBSTRATES FOR A SELF-LABELING ENZYME | Ion Biosciences (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250388523-A1 | 18F-LABELED PEPTIDE LIGANDS USEFUL IN PET AND CERENKOV LUMINESCENE IMAGING | CORNELL UNIVERSITY (US) | 2025-12-25 | — | — | US | disclosed |
| US-12297157-B2 | 18F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging | CORNELL UNIVERSITY (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2024243471-A2 | FLUORESCENT INDICATORS FOR METAL ION DETECTION AS SUBSTRATES FOR A SELF-LABELING ENZYME | ION Biosciences (US) | 2024-11-28 | — | — | WO | disclosed |
| CN-117551445-B | Petroleum fracturing propping agent based on solid waste and preparation method thereof | 铜川秦瀚陶粒有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-117551445-A | Petroleum fracturing propping agent based on solid waste and preparation method thereof | 铜川秦瀚陶粒有限责任公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4249005-A2 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | Cornell University (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3493856-B1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | UNIV CORNELL (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20060293311-A1 | e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006133426-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-0748800-B1 | Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-09 | — | — | EP | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5688795-A | URINARY TRACTS OBSTRUCTION | SYNTEX (U.S.A.) INC. (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| US-4027037-A | ARTHROPOD METAMORPHOSIS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-31 | — | — | US | disclosed |
| US-3978091-A | FUNGICIDES, INSECTICIDES, NEMATOCIDES | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | MAOB 3239/4885ALDH1A1 3966/4885CYP1A2 2341/4885 |
| US-20250388523-A1 | 18F-LABELED PEPTIDE LIGANDS USEFUL IN PET AND CERENKOV LUMINESCENE IMAGING | SCTR, SSTR3, SSTR1 | MAOB 3159/4885ALDH1A1 4778/4885CYP1A2 4529/4885 |
| US-12297157-B2 | 18F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging | VIP, CALCA, GLP1R | MAOB 3230/4885ALDH1A1 4664/4885CYP1A2 4809/4885 |
| US-20060293311-A1 | e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | JAK3, JAK1, JAK2 | MAOB 2526/4885ALDH1A1 3005/4885CYP1A2 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.